|
gptkbp:instanceOf
|
gptkb:drug
gptkb:intravenous_immunoglobulin
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
1986
|
|
gptkbp:ATCCode
|
gptkb:J06BA02
|
|
gptkbp:contains
|
gptkb:immunoglobulin_G
|
|
gptkbp:contraindication
|
IgA deficiency with antibodies against IgA
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:halfLife
|
23-25 days
|
|
gptkbp:indication
|
autoimmune diseases
immunodeficiency disorders
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:marketedIn
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
provides passive immunity by supplying antibodies
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
chills
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:usedFor
|
gptkb:chronic_inflammatory_demyelinating_polyneuropathy
gptkb:immunodeficiency
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Takeda_Pharmaceutical_Company
gptkb:Takeda_Pharmaceutical
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gammagard
|